Chemokine Therapeutics Corp. - Product Pipeline Review - Q4 2010

GlobalData, November 2010, Pages: 32

Chemokine Therapeutics Corp. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Chemokine Therapeutics Corp. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Chemokine Therapeutics Corp. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Chemokine Therapeutics Corp. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Chemokine Therapeutics Corp. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Chemokine Therapeutics Corp.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Chemokine Therapeutics Corp.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Chemokine Therapeutics Corp. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Chemokine Therapeutics Corp.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Chemokine Therapeutics Corp..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Chemokine Therapeutics Corp. and identify potential opportunities in those areas.

List of Tables
List of Figures
Chemokine Therapeutics Corp. Snapshot
Chemokine Therapeutics Corp. Overview
Key Information
Key Facts
Chemokine Therapeutics Corp. – Research and Development Overview
Key Therapeutic Areas
Chemokine Therapeutics Corp. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Chemokine Therapeutics Corp. – Pipeline Products Glance
Chemokine Therapeutics Corp. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Chemokine Therapeutics Corp.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Discovery Products/Combination Treatment Modalities
Chemokine Therapeutics Corp. – Drug Profiles
CTCE-9908
Product Description
Mechanism of Action
R&D Progress
CTCE-0214
Product Description
Mechanism of Action
R&D Progress
CTCE-0324
Product Description
Mechanism of Action
R&D Progress
CTCE-0422
Product Description
Mechanism of Action
R&D Progress
CTCE-0501
Product Description
Mechanism of Action
R&D Progress
CTCE-0012
Product Description
Mechanism of Action
R&D Progress
Chemokine Therapeutics Corp. – Pipeline Analysis
Chemokine Therapeutics Corp. – Pipeline Products by Therapeutic Class
Chemokine Therapeutics Corp. Pipeline Products By Target
Chemokine Therapeutics Corp. – Pipeline Products by Route of Administration
Chemokine Therapeutics Corp. – Pipeline Products by Molecule Type
Chemokine Therapeutics Corp. - Dormant Projects
Chemokine Therapeutics Corp. – Locations And Subsidiaries
Head Office
Recent Developments
Aug 21, 2008: Chemokine Therapeutics Receives Approval To Begin Phase II Trial Of CTCE-9908 In Liver Cancer From Hong Kong to Commence
Oct 26, 2007: Chemokine Therapeutics Presents Preliminary Results Of CTCE-9908 Phase I/II Clinical Trial
Sep 19, 2007: Juravinski Cancer Centre Investigator To Present Phase I/II Data At The Molecular Targets And Cancer Therapeutics International Conference On Chemokine’s Lead Drug Candidate, CTCE-9908
Mar 12, 2007: Chemokine Therapeutics Announces Preliminary Results Of CTCE-9908 Phase IB/II Clinical Trial In Late Stage Cancer Patients
Dec 21, 2006: Chemokine Therapeutics Announces Results Of Phase I Clinical Trials Of CTCE-0214
Jul 20, 2006: Chemokine Therapeutics to Present Data on Its Blood Vessel Regeneration Compound CTCE-0324 at 2006 Gordon Research Conference on Chemotactic Cytokines.
May 26, 2006: Chemokine Therapeutics Announced Publication Of An Article On CTCE-0012 In Nature Medicine
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans
• The Future of the Biodefense Industry: Regulation, Funding Opportunities & Company Profiles
• eLEARNING - Global Strategic Business Report
• Charter Schools - Global Outlook
• Aerospace and Defense Industry - Global Strategic Business Report
• Commercial And Military Flight Simulation - Global Strategic Business Report
• Sports and Fitness Nutrition - Global Strategic Business Report
• Education Services - Global Strategic Business Report
• Israel Life Sciences Market Analysis
• International Military and Government Helicopter Survey